乙酰胆碱激发试验对ANOCA诊断的增量价值:美国多中心FlowLab研究
FlowLab研究纳入美国14个中心因疑似心绞痛接受冠脉造影并行ANOCA评估的患者,比较是否开展乙酰胆碱痉挛激发试验对诊断和管理的影响。结果显示,在热稀释法基础上加做痉挛激发试验可使诊断阳性率从34.4%提升至84.8%,并促进按内型调整药物治疗。
要点
- ANOCA评估中加做乙酰胆碱痉挛激发试验可显著提高诊断阳性率。
- 痉挛阳性者更常强化钙通道阻滞剂治疗。
- 不同中心是否开展痉挛激发试验反映诊疗流程存在差异。
核心结论
- 在当代美国实践中,在团注热稀释法基础上加做痉挛激发试验可使诊断阳性率提高一倍以上,并促使按诊断内型调整用药。
研究设计与样本
- FlowLab研究为前瞻性、多中心、美国研究,纳入转诊行冠脉造影并采用团注热稀释法进行ANOCA评估的患者。
- 共纳入14个美国中心253例操作,其中开展痉挛激发试验的中心155例,未开展的中心98例。
主要发现
- 开展痉挛激发试验的中心在导管术前怀疑心外膜冠心病为心绞痛原因的比例低于未开展中心(27% vs. 59.2%,p<0.0001)。
- 开展痉挛激发试验的中心诊断CMD的比例高于未开展中心(68% vs. 29.6%,p<0.0001)。
- 在125例接受痉挛激发试验的患者中,诊断阳性率从单独团注热稀释法的34.4%提升至加做痉挛激发试验后的84.8%(p<0.001)。
- 心外膜痉挛(67%)和微血管痉挛(41%)患者较无痉挛者(24%)更常强化钙通道阻滞剂治疗(p=0.001)。
临床怎么用
- 对ANOCA患者,在冠脉功能学评估中应考虑加做乙酰胆碱痉挛激发试验以提高诊断率并指导分型治疗。
- 痉挛阳性患者可优先考虑钙通道阻滞剂强化治疗。
局限性
- 开展与未开展痉挛激发试验的中心之间存在操作流程差异,可能影响比较结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background Angina with non-obstructive coronary arteries (ANOCA) is an underrecognized cause of angina with non-universal diagnostic techniques and patient management strategies. Among ANOCA testing, vasospasm provocation is not always performed mainly due to differences in institutional availability. Aims Using the FlowLab Study, we quantified vasospasm prevalence among patients with ANOCA at US centers and compared physician decision-making, endotype distribution, and management between sites that did and did not include vasospasm testing in their workup. Methods The FlowLab Study was a prospective, multicenter, US-based study of patients who were referred for coronary angiography and underwent ANOCA testing using the bolus thermodilution method. Presumed diagnosis before cardiac catheterization and final diagnosis after ANOCA testing were compared between participating sites with or without acetylcholine testing availability. Results A total of 253 procedures at 14 US sites were included in this study. There were 155 procedures among sites performing spasm provocation testing and 98 procedures among sites not performing spasm provocation testing. Prior to cardiac catheterization, sites with spasm provocation testing were less likely to suspect epicardial coronary artery disease as the cause of angina compared to sites without (27% vs. 59.2%, p < 0.0001). A diagnosis of CMD was made more frequently at sites performing spasm testing compared to sites not performing spasm testing (68% vs. 29.6%, p < 0.0001). Similarly, among 125 patients who underwent spasm provocation testing, diagnostic yield increased from 34.4% with bolus thermodilution alone to 84.8% after the addition of spasm provocation testing (p < 0.001). In these patients, intensification involving calcium channel blockers was more frequent with epicardial (67%) and microvascular spasm (41%) than without spasm (24%, p = 0.001). Conclusions In contemporary US practice, adding spasm provocation testing to bolus thermodilution more than doubled diagnostic yield and was followed by medication changes directed toward the diagnosed endotype. Differences between sites with and without spasm testing also reflected variation in procedural practice.
引用
- Catheterization and Cardiovascular Interventions:Additive Value of Acetylcholine Testing in ANOCA: A US‐Based Multicenter FlowLab Study
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。